Key result
ALDOC and lysophosphatidylcholines (LPCs) were identified as key differential biomarkers that can effectively distinguish between QDLS and QDYD syndromes in patients with non-small cell lung cancer.
Why the study?
Individual characteristics of different traditional Chinese medicine syndromes in NSCLC patients may be revealed by highly specific molecular profiles to support individualized diagnosis and treatment.
Do integrated proteomics and lipidomics profiles differentiate NSCLC patients with QDLS and QDYD Traditional Chinese Medicine syndromes?
Comparison
QDYD syndrome vs QDLS syndrome vs healthy volunteers
Authors
Loading...
ALDOC and LPCs may aid TCM syndrome differentiation in NSCLC; leaves open clinical utility pending prospective validation.
Observational (n=30)
No
Do integrated proteomics and lipidomics profiles differentiate NSCLC patients with QDLS and QDYD Traditional Chinese Medicine syndromes?
Integrated proteomics and lipidomics identified ALDOC and LPCs as potential biomarkers to differentiate TCM syndromes in advanced NSCLC patients, providing a molecular basis for individualized diagnosis.
Cang et al. (2021) conducted an observational in Non-small cell lung cancer (NSCLC) (n=30). TCM syndromes (QDLS and QDYD) vs. Healthy volunteers was evaluated on Differential protein and lipid expression profiles. ALDOC and lysophosphatidylcholines (LPCs) were identified as key differential biomarkers that can effectively distinguish between QDLS and QDYD syndromes in patients with non-small cell lung cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: